Jim Cramer Urges Patience With Eli Lilly and Company (LLY)'s Stock

We recently published 9 Stocks On Jim Cramer’s Radar . Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer recently discussed.

Weight loss drug giant Eli Lilly and Company (NYSE:LLY)’s shares have lost 5.9% year-to-date as investors have questioned the firm’s weight loss drug trials. Cramer has been a fan of the firm throughout this year despite the share price woes. This time, he discussed Eli Lilly and Company (NYSE:LLY) after the firm’s latest orforglipron drug trial shared results of the treatment in patients with weight complications and diabetes:

“One of my favorite executives is David Ricks, from Eli Lilly. He came on after that last trial and that was the, a trial for weight loss, obviously, August 7th 2025, he said look, our stock shouldn’t be down that much. There’s a lot more things in the pipeline. He then bought 1,632 shares at 645, August 12th. . . well of course, the new trial, another trial came out today, August 26th, same kind, the misinformation on this thing is so [inaudible] that you gotta listen. This trial attained to, said the population was adults with obesity or overweight and type two. That’s important, the ‘and.’ Okay. Previous one was just without diabetes. They have similar results. . . no, if you include people who have diabetes it’s much harder to lose weight. So this trial is dramatic. Because if you exclude that population and you take a pill, and you’re heavy? You’re going to lose a huge amount of weight. This is a gigantic win. Is it worth 31? No, it’s probably worth maybe 80, 90. It’s that it was apples to oranges, and the apples to oranges is a tougher group of people to lose weight. David Ricks is so good. And I wish he’d come on our show. Because he could have explained very quickly. Please, there are many more pill studies.”

While we acknowledge the potential of LLY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.